{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-074712","form_type":"8-K","ticker":"GPCR","cik":"0001888886","company_name":"Structure Therapeutics Inc.","filed_at":"2025-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.519118+00:00","generated_at":"2026-05-17T19:59:22.793087+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Structure Therapeutics reports Q2 net loss $61.7M; cash $786.5M; aleniglipron data on track for year-end 2025","bullets":["Net loss $61.7M vs $26.0M YoY; R&D expenses $54.7M (up from $22.1M) due to advancing GLP-1 program.","Cash, equivalents, and short-term investments $786.5M; expected to fund operations through at least 2027.","Topline data from aleniglipron ACCESS and ACCESS II studies on track for year-end 2025 readouts.","Three new aleniglipron studies initiated: maintenance switching, body composition, T2DM, with enrollment Q3/Q4 2025.","ACCG-2671 (oral amylin) Phase 1 initiation planned by year-end 2025; preclinical data presented."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-074712","json":"https://secwatch.observer/filing/0001104659-25-074712.json","markdown":"https://secwatch.observer/filing/0001104659-25-074712.md","text":"https://secwatch.observer/filing/0001104659-25-074712.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1888886/000110465925074712/0001104659-25-074712-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1888886/000110465925074712/tm2522431d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T19:59:22.793087+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}